Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Integrating Clinical and Translational Research Networks—Building Team Medicine—Series 3
share announcement

Integrating Clinical and Translational Research Networks—Building Team Medicine—Series 3

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: 5 October 2024 | Viewed by 1351

Special Issue Editors

Prof. Dr. Ravi Salgia

E-Mail Website
Guest Editor
Chairman, Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA
Interests: lung cancer; thoracic oncology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Prakash Kulkarni

E-Mail Website
Guest Editor
Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA
Interests: cancer systems biology; evolution; non-genetic mechanisms; intrinsically disordered proteins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The previous Special Issue Series of the Journal of Clinical Medicine, entitled ‘Integrating Clinical and Translational Research Networks—Building Team Medicine’, highlighted our collective experience from the City of Hope and was well received. Thus far, the two Series published in 2021 and 2023, which included a total of 33 articles, have thus far received over 75,000 views; these have articles have been collectively cited more than 135 times.

Buoyed by the enthusiastic response from our peers and colleagues, we have embarked on establishing Volume 3. The basic theme is the same, namely integrating academic medical centers with community hospitals to ensure that all patients regardless of their physical proximity to major medical institutions can benefit from recent clinical advances. However, in Volume 3, we have ventured to include our colleagues internationally. Our aim here is to highlight translational research approaches that leverage the combined knowledge, skills, experience, expertise, and vision of clinicians in academic medical centers and their affiliated community centers and hospitals, together with those of basic research scientists, computational scientists, bioinformaticians and data scientists. We look forward to sharing our Team Medicine experience with our colleagues and trust that they will find the approach described in the articles embodied in this Special Issue helpful in guiding their approach to treating cancer patients.

Prof. Dr. Ravi Salgia
Prof. Dr. Prakash Kulkarni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • translational research
  • team medicine
  • health care reform
  • clinical advances
  • emerging inter- and cross-disciplinary
  • team-oriented culture

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

17 pages, 1769 KiB  
Perspective
Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research
by Pankaj Garg, Siddhika Pareek, Prakash Kulkarni, Ravi Salgia and Sharad S. Singhal
J. Clin. Med. 2024, 13(12), 3466; https://doi.org/10.3390/jcm13123466 - 13 Jun 2024
Viewed by 476
Abstract
Nanoengineering has emerged as a progressive method in cancer treatment, offering precise and targeted delivery of therapeutic agents while concurrently reducing overall toxicity. This scholarly article delves into the innovative strategies and advancements in nanoengineering that bridge the gap between clinical practice and [...] Read more.
Nanoengineering has emerged as a progressive method in cancer treatment, offering precise and targeted delivery of therapeutic agents while concurrently reducing overall toxicity. This scholarly article delves into the innovative strategies and advancements in nanoengineering that bridge the gap between clinical practice and research in the field of cancer treatment. Various nanoengineered platforms such as nanoparticles, liposomes, and dendrimers are scrutinized for their capacity to encapsulate drugs, augment drug efficacy, and enhance pharmacokinetics. Moreover, the article investigates research breakthroughs that drive the progression and enhancement of nanoengineered remedies, encompassing the identification of biomarkers, establishment of preclinical models, and advancement of biomaterials, all of which are imperative for translating laboratory findings into practical medical interventions. Furthermore, the integration of nanotechnology with imaging modalities, which amplify cancer detection, treatment monitoring, and response assessment, is thoroughly examined. Finally, the obstacles and prospective directions in nanoengineering, including regulatory challenges and issues related to scalability, are examined. This underscores the significance of fostering collaboration among various entities in order to efficiently translate nanoengineered interventions into enhanced cancer therapies and patient management. Full article
(This article belongs to the Special Issue Integrating Clinical and Translational Research Networks—Building Team Medicine—Series 3)
►▼ Show Figures

Figure 1

15 pages, 3544 KiB  
Perspective
Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies
by Sravani Ramisetty, Ayalur Raghu Subbalakshmi, Siddhika Pareek, Tamara Mirzapoiazova, Dana Do, Dhivya Prabhakar, Evan Pisick, Sagun Shrestha, Srisairam Achuthan, Supriyo Bhattacharya, Jyoti Malhotra, Atish Mohanty, Sharad S. Singhal, Ravi Salgia and Prakash Kulkarni
J. Clin. Med. 2024, 13(11), 3337; https://doi.org/10.3390/jcm13113337 - 5 Jun 2024
Viewed by 524
Abstract
Cancer cells, like all other organisms, are adept at switching their phenotype to adjust to the changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a fitness advantage to the cancer cell by altering its phenotype to suit environmental [...] Read more.
Cancer cells, like all other organisms, are adept at switching their phenotype to adjust to the changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a fitness advantage to the cancer cell by altering its phenotype to suit environmental circumstances. Until recently, new traits, especially in cancer, were thought to arise due to genetic factors; however, it is now amply evident that such traits could also emerge non-genetically due to phenotypic plasticity. Furthermore, phenotypic plasticity of cancer cells contributes to phenotypic heterogeneity in the population, which is a major impediment in treating the disease. Finally, plasticity also impacts the group behavior of cancer cells, since competition and cooperation among multiple clonal groups within the population and the interactions they have with the tumor microenvironment also contribute to the evolution of drug resistance. Thus, understanding the mechanisms that cancer cells exploit to tailor their phenotypes at a systems level can aid the development of novel cancer therapeutics and treatment strategies. Here, we present our perspective on a team medicine-based approach to gain a deeper understanding of the phenomenon to develop new therapeutic strategies. Full article
(This article belongs to the Special Issue Integrating Clinical and Translational Research Networks—Building Team Medicine—Series 3)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop